We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

85 hedge funds and large institutions have $4.75M invested in VistaGen Therapeutics in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $4K | Put options by funds: $2K

0.25% less ownership

Funds ownership: 0.91% → 0.66% (-0.25%)

8% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 25

8% less funds holding

Funds holding: 92 → 85 (-7)

41% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 17

48% less capital invested

Capital invested by funds: $9.13M → $4.75M (-$4.39M)

Holders
85
Holders Change
-7
Holders Change %
-7.61%
% of All Funds
1.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
23
Reduced
25
Closed
17
Calls
$4K
Puts
$2K
Net Calls
+$2K
Net Calls Change
-$401K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$71.9K
2
State Street
State Street
Massachusetts
+$66.6K
3
Northern Trust
Northern Trust
Illinois
+$30.9K
4
GWSG
GPS Wealth Strategies Group
Colorado
+$30.9K
5
UBS Group
UBS Group
Switzerland
+$22.9K

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$1.38M
2
Renaissance Technologies
Renaissance Technologies
New York
-$459K
3
MCM
MAI Capital Management
Ohio
-$155K
4
Millennium Management
Millennium Management
New York
-$93.7K
5
Simplex Trading
Simplex Trading
Illinois
-$52.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
AB
51
Amalgamated Bank
New York
$3K – – –
T. Rowe Price Associates
52
T. Rowe Price Associates
Maryland
$3K +$2.01K +534 +89%
Cambridge Investment Research Advisors
53
Cambridge Investment Research Advisors
Iowa
$3K +$2.03K +540 +154%
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$3K +$3.29K +873 +1,105%
PCA
55
Personal Capital Advisors
California
$2.79K +$3.4K +903 New
ProShare Advisors
56
ProShare Advisors
Maryland
$2.74K +$651 +173 +24%
AIP
57
Ameritas Investment Partners
Nebraska
$2.69K – – –
FAIM
58
Financial Advocates Investment Management
Washington
$2.38K +$2.9K +770 New
Legal & General Group
59
Legal & General Group
United Kingdom
$2.14K – – –
CTA
60
Chesley Taft & Associates
Illinois
$2.06K – – –
UBV
61
United Bank (Virginia)
Virginia
$2.06K – – –
GCA
62
Genesee Capital Advisors
New York
$2.05K – – –
SG Americas Securities
63
SG Americas Securities
New York
$2K -$12.3K -3,256 -82%
MML Investors Services
64
MML Investors Services
Massachusetts
$2K – – –
HFM
65
Hartford Financial Management
Connecticut
$1.65K – – –
EA
66
Echo45 Advisors
California
$1.61K +$1.97K +522 New
SS
67
Simplicity Solutions
Minnesota
$1.5K – – –
BFG
68
Bleakley Financial Group
New Jersey
$1.5K +$1.82K +485 New
Mackenzie Financial
69
Mackenzie Financial
Ontario, Canada
$1.42K – – –
TLCM
70
Twin Lakes Capital Management
California
$1.29K – – –
BWM
71
Boyd Wealth Management
California
$1.25K – – –
State Board of Administration of Florida Retirement System
72
State Board of Administration of Florida Retirement System
Florida
$1.2K +$1.46K +387 New
X
73
Xponance
Pennsylvania
$1.17K +$94 +25 +7%
AQR Capital Management
74
AQR Capital Management
Connecticut
$1.07K +$1.3K +346 New
Prudential Financial
75
Prudential Financial
New Jersey
$1.04K – – –
1 2
3
4 5

VTGN Hedge Fund Activity: Q4 2022 in Review

85 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2022, worth a combined $4.75M — down 48% from $9.13M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of VTGN and 10 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 23 added.

The largest buyer was BlackRock, adding an estimated $71.9K. The largest seller was Franklin Resources, exiting entirely with an estimated $1.38M sold.

  • 85 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2022, down from 92 in Q3 2022.
  • Funds reported $4.75M of VistaGen Therapeutics stock for Q4 2022, down 48% quarter-over-quarter.
  • 10 funds opened new VistaGen Therapeutics positions in Q4 2022 and 17 closed out, a net change of -7 holders.
  • The largest VistaGen Therapeutics buyer in Q4 2022 was BlackRock, an estimated $71.9K added.
  • The largest VistaGen Therapeutics seller in Q4 2022 was Franklin Resources, an estimated $1.38M sold.

Based on aggregated 13F filings for Q4 2022.